These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25142233)

  • 1. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
    Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
    Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
    Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
    Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods.
    Mahdavi M; Mohabatkar H; Keyhanfar M; Dehkordi AJ; Rabbani M
    Asian Pac J Cancer Prev; 2012; 13(7):3053-9. PubMed ID: 22994709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production and Characterization of New Anti-HER2 Monoclonal Antibodies.
    Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
    Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):213-21. PubMed ID: 26090600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
    Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
    BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
    Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
    Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.
    Sadri-Ardalani F; Ahmadi M; Hemmati A; Emami S; Farid S; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
    Iran J Immunol; 2017 Jun; 14(2):99-110. PubMed ID: 28630381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes.
    Deng X; Zheng X; Yang H; Moreira JM; Brünner N; Christensen H
    PLoS One; 2014; 9(9):e106448. PubMed ID: 25192037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles.
    Pouyanfard S; Bamdad T; Hashemi H; Bandehpour M; Kazemi B
    PLoS One; 2012; 7(11):e49539. PubMed ID: 23166703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes.
    Gangwar RS; Shil P; Sapkal GN; Khan SA; Gore MM
    Virus Res; 2012 Jan; 163(1):40-50. PubMed ID: 21889960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response of mice transgenic for human histocompatibility leukocyte Antigen-DR to human thyrotropin receptor-extracellular domain.
    Inaba H; Pan D; Shin YH; Martin W; Buchman G; De Groot LJ
    Thyroid; 2009 Nov; 19(11):1271-80. PubMed ID: 19725778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
    Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
    J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
    Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
    Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
    Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
    Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
    Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
    Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
    Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
    Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
    Garrett JT; Rawale S; Allen SD; Phillips G; Forni G; Morris JC; Kaumaya PT
    J Immunol; 2007 Jun; 178(11):7120-31. PubMed ID: 17513761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis.
    Khan AA; Babu JP; Gupta G; Rao DN
    Vaccine; 2008 Jan; 26(3):316-32. PubMed ID: 18096277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
    Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
    Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.